Achillion Pharmaceuticals, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported revenues of $15,000,000 compared to $31,591,000 a year ago. Loss from operations was $5,289,000 compared to income from operations of $16,499,000 a year ago. Net loss was $4,429,000 or $0.03 per basic and diluted share compared to net income of $16,952,000 or $0.12 per basic and diluted share a year ago.

For the year, the company reported revenues of $15,000,000 compared to $66,122,000 a year ago. Loss from operations was $64,865,000 compared to $15,107,000 a year ago. Net loss was $61,706,000 or $0.45 per basic and diluted share compared to $5,030,000 or $0.04 per basic and diluted share a year ago.

The company provided earnings guidance for the year 2017. The company expects net cash used in operating activities in 2017 will be approximately $70 - 75 million based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs. The net loss per share for fiscal 2017 is anticipated to approximate $0.70 - 0.75 per share.